Background Previous phase I-II studies have shown that the combination of paclitaxel-cisplatin-etoposide (TEP) is very active and well tolerated in patients with small-cell lung cancer (SCLC) In order to compare the TEP combination to cisplatinetoposide (EP) regimen as front-line treatment in patients with SCLC, we conducted a randomised multicenter study
Summary
Background Previous phase I-II studies have shown that the combination of paclitaxel-cisplatin-etoposide (TEP) is very active and well tolerated in patients with small-cell lung cancer (SCLC) In order to compare the TEP combination to cisplatinetoposide (EP) regimen as front-line treatment in patients with SCLC, we conducted a randomised multicenter study
Patients and methods One hundred thirty-three chemotherapy-naive patients with histologically proven limited or extensive stage SCLC were randomised to receive either paclitaxel 175 mg/m 2 I v three-hour infusion on day 1 and cisplatin 80 mg/m 2 l v on day 2 and etoposide 80 mg/m 2 l v on days 2-4 with G-CSF support (5 mcg/kg s c days [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] or cisplatin 80 mg/m 2 I v on day 1 and etoposide 120 mg/m 2 I v on days 1-3 in cycles every twenty-eight days Results Due to excessive toxicity and mortality observed in the TEP arm, an early interim analysis was performed and the study was closed Sixty-two patients received two hundred sixty-one cycles of TEP and seventy-one patients three hundred twenty-three cycles of EP The two patient groups were well balanced for age, sex, performance status, stage of disease and the presence of abnormal LDH at diagnosis In an intentionto-treat overall analysis both regimens were equally active with a complete and partial response rate of 50% (95% confidence interval (CI) 37 5%-62 4%) forTEPand 48% (95% Cl 36 2%-59 5%) for EP (P = 0 8) The median time to disease progression was 11 months for TEP and 9 months for EP (P = 0.02). The duration of response, one-year survival and overall survival were similar in the two arms. Similarly, in an intention-to-treal subgroup analysis of patients with limited or extensive stage disease, there was no difference in the activity between the two regimens except of a longer median time to disease progression in the extensive stage in favour of the TEP regimen, eight versus-six months (P = 0 04) However, there were eight toxic deaths in the TEP arm versus none in the EP arm (P -0 001) Moreover, the TEP regimen was associated with more severe toxicity than the EP regimen in terms of grade 4 neutropenia (P = 0.04), grade 3-4 thrombocytopenia (P = 0 02), febrile neutropenia (P = 0 08), grade 3-4 diarrhea (P -0.01), grade 3-4 asthenia (P = 0 05) and grade 3 neurotoxicity (P = 0 06)
Introduction
Small-cell lung cancer (SCLC) is initially a chemosensitive disease for the majority of patients and combination chemotherapy has prolonged the survival of patients with limited or extensive disease. When combination regimens containing a platinum compound and etoposide are used, response rates of 60%-90% with 10%-50% complete responses are usually achieved, resulting in a median survival of patients with limited and extensive stage of 15-20 months and 7-10 months, respectively [1] [2] [3] [4] . Although partial and complete responses to combination chemotherapy are common, SCLC remains an incurable disease for most patients due to the emergence of resistant clones which are refractory to further treatment. Therefore clinical research is focusing on new agents which are active in SCLC and possibly non-cross resistant with the older drugs.
Pachtaxel has been studied in previously untreated as well as in treatment refractory SCLC patients with promising results. In two phase II studies in chemotherapy-naive, extensive stage SCLC patients, single-agent paclitaxel at 250 mg/m 2 given as a 24-hour infusion produced response rates of 34%-53% [5, 6] . In another phase II study in heavily pretreated SCLC patients, single-agent paclitaxel at 175 mg/m 2 administered as a three-hour infusion gave responses in 29% of patients [7] Due to its promising activity as single agent, paclitaxel has been combined with cisplatin-etoposide or carboplatin-etoposide [8] [9] [10] [11] . From a phase I study, Bunn et [9] . Subsequently they treated 30 patients with extensive stage SCLC with the above regimen and reported an overall objective response rate of 96% with 48% of the courses complicated by grade 4 neutropenia and 6% by febrile neutropenia which resulted in 1 toxic death From the above studies it was obvious that the three-drug combination was feasible with acceptable toxicity and very promising activity in extensive stage SCLC In order to compare the three-drug regimen versus the 'standard' two-drug combination, a randomized multicenter study was conducted in previously untreated patients with SCLC The primary endpoint of the study was to compare the two regimens in terms of the response rate they produce. Secondary endpoints were to compare the time to disease progression and overall survival as well as the associated toxicity with each regimen.
Patients and methods

Criteria for eligibility
Eligibility criteria included histologically or cytologically documented SCLC, limited or extensive stage disease, no prior chemotherapy, age 18-75 years, performance status by World Health Organization (WHO) <2 and the presence of bidimensionally measurable and not previously irradiated disease In addition patients had to have adequate organ function with absolute neutrophil count (ANC) ^ 1500/u.l, platelet count ^ 100,000/ul, serum creatinine < I 5 mg/dl, serum AST and ALT values < 1 5 times the upper limit of normal, serum bihrubin < 1 5 mg/dl, absence of active infection or malnutrition and no history of any other malignancy in the preceding five years other than nonmelanoma skin cancer or in s/m cervical carcinoma Patients with second-or third-degree heart block, bundle-branch block, or a history of ventricular arrhythmias or angina pectons were excluded. Patients with brain metastases were allowed to participate if they had previously received cranial irradiation with clinical and radiographic improvement The study was approved by the Ethics and Scientific committees of the participating hospitals and all patients were required to sign a written informed consent prior to study entry
Prctrcatment and staging procedures
Each patient underwent the following staging procedures to assess the presence or absence of metastatic disease chest X-ray (posterioranterior and lateral views), computed tomography (CT) scans of the chest, the brain and the abdomen, radionuchde bone scan, and bone marrow aspiration and biopsy in patients with apparently limited disease Pretreatment assessment also included haematological and biochemical tests, an EKG as well as the measurement of serum lactic dehydrogenase (LDH) level
Patients were considered to have limited stage disease when detectable cancer was limited to one lung, mediastinum, and ipsilateral supraclavicular lymph nodes Patients with malignant pericardia! or pleural effusion were considered to have extensive stage disease
Study design
Randomization procedure
Patients were randomized by a centralized telephone assignment procedure to receive either the combination of pachtaxel-cisplatin-etoposide (TEP) or the combination of cisplatin-etoposide (EP) A stratified randomization procedure was followed, randomization parameters included the patient's age (according to 10- Patients with progressive disease at any time were withdrawn from the study, patients with stable disease, complete remission (CR) or partial remission (PR) received a maximum of six cycles, and patients with a continuing response received a maximum of nine cycles For both regimens, dose-adjustment criteria were based on toxicity and included 25% dose reduction of all drugs in case of febrile neutropenia or grade 4 neutropenia or thrombocytopenia lasting more than five days or any > grade 3 non-haematologic toxicity, in the absence of fever, all drugs were reduced by 15% if the nadir ANC was below 500/ul and platelets less than 50,000/ul Dose reductions were maintained for all subsequent cycles of treatment
To xicity and response evaluation
In order to assess toxicity, a complete medical history was obtained and a thorough physical examination was performed with a complete blood count (CBC), biochemical profile and an EKG before each cycle During treatment a CBC with differential was performed weekly and in cases of grade 3-4 neutropenia or thrombocytopenia or febrile neutropenia it was performed daily until haematologic recovery Response to treatment was assessed in all patients by physical examination and chest X-rays after each cycle, and by CT scans or ultrasound after every three cycles of chemotherapy or sooner if clinically indicated Any (90) 7 (10) 21 (30) 42 (59) 8 (11) 30 (42) 41 (58) 39 (55) 10 (14) 30 (42) 31 (44) 71 (100) 58 (82) 18 (25) 15 (21) 10 (14) 12 (17) 9 (13) staging investigation that yielded previously abnormal results was also repeated after every three cycles of chemotherapy Imaging studies were reviewed by a panel of independent radiologists A complete response (CR) was defined as the disappearance of all malignant lesions documented by clinical, radiologic, and endoscopic methods lasting a minimum of one month A partial response (PR) was defined as a decrease ^ 50% in the size of all measurable lesions lasting at least one month without any new tumour lesion Progressive disease (PD) was defined as > 25% increase of the cross-sectional area of one or more lesions or development of new lesions irrespective of response elsewhere Stable disease (SD) was defined as the criteria which fall in between PR and PD All patients who received at least three cycles were evaluable for response and all patients who received at least one cycle were evaluable for toxicity Toxicities and response to treatment were scored based on standard WHO criteria [12] Radiotherapy Limited stage disease patients were scheduled to receive thoracic radiation (50 Grays in 25 fractions) after the completion of chemotherapy The effect of thoracic radiation was not considered in the evaluation of response Patients with limited disease achieving a complete response were also recommended to receive prophylactic brain radiation after the completion of chemotherapy (30 Grays in 10 fractions over 14 days using 2 lateral fields) Radiotherapy was scheduled to start within two months from the completion of chemotherapy
Sample size
The primary end-point was the comparison of the response rate in the two treatment arms The study was designed to have 80% power to detect an improvement in the overall response rate from 70% with EP to 80% with TEP at the one-sided 5% level of statistical significance This improvement with TEP was predicted by the results of previous phase 1 -II studies [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] A total of 460 patients (230 patients on each arm) were planned to enter the study in order to achieve the statistical requirements of the fixed sample size design [13] Two interim analyses were scheduled to be performed after response data became available for the first one-third and two thirds of the study patients Since the primary comparison would be between the response rates in the two treatment arms, the predefined criteria for considering trial closure at the interim analysis time points were if TEP was superior at the statistically significant level of 2 5% or was associated with excessive toxicity as compared to the EP arm Although they were not included in the boundary criteria, separate sub-group analyses were planned for patients with limited and extensive stage disease
Statistical analysis
All clinical data were centrally collected and analysed (Clinical Trial Office, Department of Medical Oncology, University General Hospital of Herakhon, Crete) using the SPSS version 8 0 statistical software Analysis was performed on an intent-to-treat basis provided that the main inclusion criteria were satisfied The duration of response was measured from the day of the first documentation of response to chemotherapy until disease progression The time to disease progression was measured from study entry until the day of the first evidence of disease progression Overall survival was measured from sludy entry to death or last contact The probability of survival was estimated by the method of Kaplan and Meier [14] and tested for differences by using the log-rank test The 95% confidence intervals (Cl) for response rates were calculated using methods for exact binomial confidence intervals [15] Qualitative factors were compared by the Pearson's x 2 contingency table analysis [16] All tests were two-sided and were considered significant when the resulting /"-value was < 0 05
Results
Early trial termination
The trial was stopped in March 1999 after obtaining the results of an early interim analysis triggered by the high number of toxic deaths observed on the TEP arm. The early interim analysis was performed when 133 eligible patients had been enrolled and showed no difference in the response rates between the 2 arms but showed a higher mortality rate related to toxicity in the TEP arm (8 toxic deaths on TEP versus none on EP; P = 0.001) It was therefore decided to stop further patient accrual because of the high treatment-related mortality rate estimated at 13% in the TEP group versus 0% in the EP group
Patient charactenstics
Between July 1997 and March 1999, 133 chemotherapynaive patients with SCLC were enrolled onto the study. According to the predefined stratified randomization at the time trial was closed, 62 patients were randomized to receive TEP and 71 EP. Patients' characteristics are shown in Table 1 The two groups were well balanced in terms of age, sex, performance status, disease stage, number of sites involved and presence of increased LDH at diagnosis. Thirty-three (53%) patients on TEP and forty-one (58%) on EP had extensive stage disease. Performance status (WHO) was 0-1 in 55 (89%) patients on TEP and 63 (89%) on EP. All patients in both groups were evaluable for toxicity and 49 (79%) patients on TEP versus 69 (97%) on EP were evaluable for response to treatment The reasons why 13 patients on TEP were not evaluable for response included early toxic death (8 patients), major protocol violation (2 patients), stopping the treatment after the first cycle due to etoposide allergy (I patient), grade 3 neurotoxicity (1 patient) and lost to follow-up after the first cycle (1 patient). The two patients on EP who were not evaluable for response included, one patient with lethal gastrointestinal haemorrhage due to a bleeding gastric ulcer who received only one cycle and another patient who was lost to follow-up after the first cycle. In the intention-to-treat analysis the above patients were considered as progressors
Overall response rates and survival
In an intention-to-treat analysis, 2 patients (3%) on TEP and 3 (4%) on EP achieved a complete remission with 29 patients (47%) on TEP and 31 (44%) on EP achieving a partial remission for an overall response rate of 50% (95% CI: 37.5%-62.4%) for TEP versus 48% (95% CI 36.2%-59.5%) for EP {P = 0 8) Furthermore 8 patients (13%) on TEP and 10 (14%) on EP had stable disease and 23 (37%) on TEP and 27 (38%) on EP had progressive disease. The median duration of response was six months (range 1-25) for TEP and six months (range 1-16) for EP (P = 0.4) Median time to disease progression was 11 months (range 2 5-27) for TEP and 9 months (range 3-18) for EP (P = 0.02). After a median follow-up time of 9 months (range 0.5-27) for patients on TEP and 10 months (range 1-30) for patients on EP, the median survival and one-year survival were 9.5 (0 5-27) months and 38.2% on TEP and 10.5 (1-30) months and 37% on EP (P = 0 9) Figure 1 shows that the probability of survival was similar for patients receiving TEP or EP.
Subgroup analysis
In an intention-to-treat subgroup analysis of responses between the two regimens based on the disease stage (limited versus extensive), there was no difference between the two arms ( Table 2 ) Furthermore, there was no difference between the two regimens in limited or extensive disease in terms of duration of response, median survival and one-year survival (Table 3) . Median time to disease progression was longer for TEP than EP in patients with extensive disease; eight (range 4-27) versus six (range 3-12) months, respectively (P = 0 04) Figures 2 and 3 show similar probabilities of survival for patients receiving TEP versus EP in limited and extensive disease, respectively
Haematologic and non-haematologic toxicity
Toxicity was evaluated in all patients and all cycles (Table 4 ) Twenty-four (39%) patients on TEP versus sixteen (22%) on EP developed grade 4 neutropenia (P = 0.04) and eleven (18%) on TEP versus four (6%) on 7 (11) 27(43) 9 (14) 14 (23) 9 (14) 2 (3) 11 (18) 20 (32) 4 (6) 3 (4) 3 (4) EP n (%) 5 (7) 25 (35) 20 (28) 23 (32) 8 (11) 3 (4) 10 (14) 33 (47) 6 (9) 5 (7) 4 (6) 2 TEP n (%)
8 (13) 14 (23) 3 (6) 11 (18) 5 (8) 2 (3) 2 (3) 13 (21) 1 (2) --
12 (17) 16 (22) 7 (10) 7 (10) 3 (4) 1 (1) 2 (3) 9 (13) 3 (4) --
12 (17) 6 (9) 2 (3) 3 (4) --
KD -EP grade 3-4 thrombocytopenia (P = 0 02). Febrile neutropenia developed in 15 (24%) patients on TEP versus 9 (13%) on EP (P = 0.08) requiring hospitalization for a median of 5 days (range 3-20) for TEP versus 6 days (range 4-24) for EP. Grade 3-4 diarrhea developed in 5 (8%) patients on TEP verms none on EP (p = 0.01), grade 3 neurotoxicity in five (8%) patients on TEP versus one (1.4%) on EP (/> = 0 06) and grade 3^4 asthenia in seven (11%) patients on TEP versus two (3%) on EP (P = 0.05). In the subgroup analysis of the toxicities of each regimen in patients with PS 0-1 vs. PS 2, only asthenia but not the other toxicities were more common in patients with PS 2 (P -0.018 for TEP, P = 0.005 for EP). There was no relationship between toxicity and type of metastases. More importantly, there were eight toxic deaths with the TEP regimen versus none with EP (P = 0.001). The toxic deaths were due to. neutropenic sepsis (4 patients), grade 4 diarrhea with possible sepsis (1 patient), stroke with pancytopenia (1 patient), pneumonia day 10 posttreatment (1 patient) and sudden death day 7 post-treatment (1 patient). The performance status (WHO) of the eight patients at enrolment was: 0 for two patients (25%), 1 for four (50%) and 2 for two (25%). Four (50%) of the toxic deaths occurred in patients with limited stage disease and four (50%) in patients with extensive disease Only one of the eight patients had liver metastases. Six (75%) of the toxic deaths occurred after the first cycle, one after the third cycle and one after the fourth cycle.
In addition there were two deaths not related to the disease or treatment in the TEP arm (one due to myocardial infarction and one due to pneumonia occurring two and seven months after treatment, respectively), and three deaths on the EP arm (due to a ruptured aortic aneurysm, a pulmonary embolism and a gastrointestinal haemorrhage from gastric ulcer without associated thrombocytopenia).
Treatment delivery and compliance
A total of 261 cycles of TEP and 323 of EP were administered with a median number of cycles per patient 5 (range 1-9) and 4 (range 1-8), respectively. The median interval between cycles was 28 days (range 28-35) for TEP and 28 days (range 28-36) for EP Eighteen (7%) cycles of TEP were delayed due to haematologic (3 cycles) and non-haematologic (2 cycles) toxicity or late patient admission due to personal reasons and pending imaging studies for response evaluation (13 cycles) Similarly, 19 (6%) cycles of EP were delayed due to haematologic (3 cycles) and non-haematologic (3 cycles) toxicity or late patient admission and pending imaging studies (13 cycles). Dose reduction due to toxicity was required in 18 patients on each arm (29% of patients receiving TEP and 25% of patients receiving EP), corresponding to 22 (8%) cycles of TEP versus 23 (7%) of EP. G-CSF was administered in all cycles of TEP and 187 (58%) cycles of EP The administered mean dose-intensity for paclitaxel was 40 mg/m 2 /week, for cisplatin 20 mg/m 2 /week and for etoposide 57.5 mg/m 2 /week (corresponding to 92%, 95% and 96% respectively of the protocol planned doses) in theTEP regimen, and 18.9 mg/m 2 /week for cisplatin and 67 3 mg/m 2 /week for etoposide (corresponding to 95% and 93%, respectively, of the protocol planned doses) in the EP regimen.
Discussion
SCLC remains an incurable disease for the majority of patients with little progress made in the last 20 years of clinical research. Patients with limited disease have a 10%-15% chance of survival at five years and have benefited from the multimodality approach combining chemotherapy with thoracic radiotherapy [2] . On the other hand, patients with distant metastases have a three-year survival rate of less than 5%> and no new drug combination has been shown to be superior to the 'classic regimen' of a platinum compound combined with etoposide [1] . It is therefore reasonable to evaluate the efficacy of new agents like paclitaxel in combination with other active drugs in the treatment of this disease. Paclitaxel as single agent has shown significant activity in previously untreated as well as in heavily pretreated patients with SCLC [5] [6] [7] Moreover pretreatment with paclitaxel has resulted in reversal of multidrug resistance in SCLC cell lines [17] . Initial results from phase I-II studies combining paclitaxel with cisplatin and etoposide were very promising showing high activity and manageable toxicity in patients with extensive stage disease [8, 9] .
In this multicenter randomized study we attempted a direct comparison of the three-drug combination versus the 'standard' two-drug regimen in previously untreated patients with limited or extensive stage SCLC Because the study was closed prematurely, even before the first scheduled interim analysis, and due to the unexpected toxicity and mortality observed with theTEP regimen, a few more patients had been randomized to the EP arm based on the predefined stratified randomization scheme of the study; nevertheless the patients' characteristics were well balanced between the two arms ( Table 1) . For the TEP arm we used the recommended doses from Bunn et al [8] and added the prophylactic administration of G-CSF due to the high incidence of grade 4 neutropenia and febrile neutropenia (95% and 21%o of patients, respectively) in the initial report The etoposide dose in the EP regimen has ranged in the literature from 80-150 mg/m 2 and for this study the dose of 120 mg/m 2 was chosen [1, [18] [19] [20] . We also administered the chemotherapy cycles for both regimens every 4 weeks to allow for recovery from treatment related toxicities Despite the above safety modifications, treatment with the TEP regimen proved to be very toxic resulting in 8 toxic deaths among 62 patients and a treatment related mortality of 13% Most of the toxic deaths (6 out of 8) occurred after the administration of the first chemotherapy cycle and affected equally patients with limited or extensive stage disease who had in general a good performance status (6 out of 8 patients had PS 0-1). Moreover, the toxic deaths occurred in different participating hospitals with experience in the management of cancer patients and therefore should be regarded as severe toxicity related to the regimen and not due to suboptimal care delivered by a specific participating center. Due to the unexpected high toxic death rate with the TEP arm, the first interim analysis was performed sooner than originally scheduled and showed the excessive toxicity and mortality of the TEP regimen without any apparent improvement in the response rate over the EP regimen. Based on the toxicity and response data of the early interim analysis and for safety reasons it was decided to close the clinical trial.
In this study complete and partial remission rates have been low compared to previously published reports for both regimens. However, this study was multicenter including university as well as public hospitals and therefore may include patients with characteristics more representative of the patient population as a whole. Such patients may have inferior outcome compared to patients included in typical phase II single institution studies [21] . Furthermore for patients with limited stage disease, the delayed rather than the early addition of thoracic irradiation, may have compromised the clinical outcome [2] . In addition, the administration of the treatment cycles every four weeks instead of every three weeks has moderately reduced dose intensity of all drugs and this may have compromised the activity of both regimens. However, according to one set of meta-analysis results, dose intensity-outcome correlations are not consistent for the EP regimen in SCLC [22] In contrast to the high response rates reported by older studies, more recent data on the activity of the TEP and EP regimens in extensive and limited SCLC show similar response rates to our results [20, 23, 24] . In our study, the activity and the efficacy of the two regimens was similar in terms of response rates, duration of responses, median survival and one-year survival. Only time to disease progression was longer with the TEP regimen, especially in patients with extensive disease (Tables 2 and 3 ). However, the conclusions drawn from our study regarding the activity of the two regimens should be considered preliminary given the statistical limitation of the small number of patients in this trial at the time of its termination Haematologic and non-haematologic toxicities were more common and more severe with the TEP regimen (Table 4) . Grade 4 neutropenia occurred in 39%> of patients (11% of cycles) with TEP versus 22% of patients (7% of cycles) with EP (P = 0.04). Febrile neutropenia was also more common with TEP than EP (24% versus 13%o, P = 0.08) and resulted in 4 septic deaths despite the prompt hospitalization and administration of intravenous antibiotics in all cases. Grade 3-4 thrombocytopenia was more common with TEP (18%> of patients, 5% of cycles) than EP (6% of patients, 2% of cycles) (P = 0.02, P -0 05, respectively). Diarrhea grade 3^4 was observed only with theTEP regimen (8%> of patients, 2% of cycles) while neurotoxicity grade 3 was observed in 8% of patients (3% of cycles) withTEP versus 1.4% of patients (0.3% of cycles) with EP (P -0 06, P = 0.007, respectively). Severe asthenia (grade 3-4) was more common with the TEP regimen (11.3% versus 3% of patients, P = 0.05%, 3.8% versus 0.6% of cycles, P = 0.006). Based on the above toxicity data there is no doubt that theTEP regimen is significantly more toxic than the EP regimen.
Our results are further supported by the data from a phase II study conducted by the Southwest Oncology Group (SWOG study 9705) using theTEP regimen with G-CSF support in previously untreated patients with extensive stage SCLC [23] . Among 90 treated patients, the overall response rate was 56% including 12% CR, and the treatment related mortality was 7% (4 deaths of neutropenic sepsis, 1 of infection and 1 of complications of renal failure) At the present time there is an ongoing randomized Intergroup trial comparing TEP to EP in extensive stage SCLC patients with a good performance status (PS 0-1) Based on the above results, the TEP combination at the drug doses used in this study, appears to be very toxic and without an obvious additional clinical benefit compared to the EP regimen. Therefore the TEP regimen should not be used outside of a protocol setting. Dose reduction of paclitaxel as well as the routine use of G-CSF are strongly recommended [25, 26] . Alternatively, the substitution ofcarboplatin instead of cisplatin may help to reduce the regimen's toxicity [11] . Furthermore, when the TEP regimen is administered concurrently with thoracic radiation the doses of all drugs should be reduced to avoid excessive toxicity [27] 
